Drug Trial Radar · NCT03072238
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Jun 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,101
Actual
Start
Jun 30, 2017
Primary completion
Mar 16, 2020
Study completion Apr 24, 2024
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Mar 7, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant prostate cancer (mCRPC).
Conditions
- Metastatic Prostate Cancer
Interventions
IpatasertibDrug
Oral tablets, 400 mg, given once daily (QD) beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.
AbirateroneDrug
Oral tablets of abiraterone, 1000 mg QD, taken on an empty stomach and swallowed whole with water.
PlaceboDrug
Oral tablets (matched to ipatasertib appearance), given QD beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.
Prednisone/PrednisoloneDrug
Oral tablets of 5 mg, taken twice daily (BID) until disease progression or intolerable toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator-assessed Radiographic Progression-free Survival (rPFS), Per Prostate Cancer Working Group 3 (PCWG3) Criteria in Phosphatase and Tensin Homolog (PTEN) Loss PopulationTime frame: Up to approximately 32 months
- Investigator-assessed rPFS, Per PCWG3 Criteria in ITT PopulationTime frame: Up to approximately 32 months
Locations
176 sites in 26 countries. Site status is shown where the registry gives one.
Ironwood Cancer & Research Centers
Chandler, Arizona
Mayo Clinic Arizona
Scottsdale, Arizona
City of Hope
Duarte, California
USC Norris Cancer Center
Los Angeles, California
UC Irvine Medical Center
Orange, California
Stanford University
Palo Alto, California
Pacific Hematology Oncology Associates
San Francisco, California
University of Colorado Hospital - Anschutz Cancer Pavilion
Aurora, Colorado
Yale Cancer Center
New Haven, Connecticut
Georgetown University Medical Center
Washington D.C., District of Columbia
Lynn Cancer Institute/Boca Raton Regional Hospital
Boca Raton, Florida
Miami Cancer Institute of Baptist Health, Inc.
Miami, Florida
Northside Hospital
Atlanta, Georgia
Illinois Cancer Care
Peoria, Illinois
Associates in Oncology/Hematology P.C.
Rockville, Maryland
Tufts Medical Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Karmanos Cancer Institute..
Detroit, Michigan
HCA Midwest Division
Kansas City, Missouri
Urology Cancer Center & GU Research Network
Omaha, Nebraska
Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley
Las Vegas, Nevada
Hackensack Univ Medical Center
Hackensack, New Jersey
Cleveland Clinic
Cleveland, Ohio
Northwest Cancer Specialists, P.C.
Tualatin, Oregon
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Allegheny Cancer Center
Pittsburgh, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Charleston Oncology, P .A
Charleston, South Carolina
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Texas Oncology - Gulf Coast
The Woodlands, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
Macquarie University Hospital
Macquarie University, New South Wales, Australia
Adelaide Cancer Centre
Kurralta Park, South Australia, Australia
Monash Medical Centre
EAST Bentleigh, Victoria, Australia
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
Eastern Health
Melbourne, Victoria, Australia
Lkh-Univ. Klinikum Graz
Graz, Austria
Ordensklinikum Linz Elisabethinen
Linz, Austria
Landeskrankenhaus Salzburg
Salzburg, Austria
Showing 40 of 176 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.